Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer
D Rischin, B Burmeister, P Mitchell, M Boyer… - Journal of Clinical …, 2004 - ascopubs.org
7077 Background: Gefitinib ('Iressa', ZD1839) enhances tumor radioresponsiveness in
preclinical studies, and is approved as monotherapy in non-small-cell lung cancer (NSCLC) …
preclinical studies, and is approved as monotherapy in non-small-cell lung cancer (NSCLC) …
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non …
T Cufer, E Vrdoljak, R Gaafar, I Erensoy… - Anti-cancer …, 2006 - journals.lww.com
Our objective was to evaluate gefitinib (IRESSA), an epidermal growth factor receptor
tyrosine kinase inhibitor, versus docetaxel as second-line monotherapy for advanced non …
tyrosine kinase inhibitor, versus docetaxel as second-line monotherapy for advanced non …
[HTML][HTML] Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer
Despite recent developments in the diagnosis and conventional treatment of non small cell
lung cancer (NSCLC), the prognosis remains unsatisfactory, with 5-year survival rates of …
lung cancer (NSCLC), the prognosis remains unsatisfactory, with 5-year survival rates of …
Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib
A Onn, M Tsuboi, N Thatcher - British journal of cancer, 2004 - nature.com
Worldwide, non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related
mortality and, until screening detects early disease, treatment for the majority of patients will …
mortality and, until screening detects early disease, treatment for the majority of patients will …
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
M Di Maio, C Gridelli, N Normanno… - Journal of cellular …, 2005 - Wiley Online Library
Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
have shown promising activity in patients with non‐small cell lung cancer (NSCLC). Gefitinib …
have shown promising activity in patients with non‐small cell lung cancer (NSCLC). Gefitinib …
[HTML][HTML] Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
CM Tsai, JT Chen, DJ Stewart, CH Chiu, CL Lai… - Journal of Thoracic …, 2011 - Elsevier
Introduction: Four phase III randomized trials adding epidermal growth factor receptor
(EGFR)-tyrosine kinase inhibitors to standard chemotherapeutics in patients with advanced …
(EGFR)-tyrosine kinase inhibitors to standard chemotherapeutics in patients with advanced …
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2004 - ascopubs.org
7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small …
LBA7005 Background: In meta-analyses, platinum-based adjuvant (adj) chemotherapy (CT)
in completely resected NSCLC increased cure rate by∼ 5%. At BR. 19 initiation, adj study …
in completely resected NSCLC increased cure rate by∼ 5%. At BR. 19 initiation, adj study …
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
TE Stinchcombe, MA Socinski - The Oncologist, 2008 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the data on the patient populations enrolled and the efficacy of erlotinib and gefitinib in the …
the data on the patient populations enrolled and the efficacy of erlotinib and gefitinib in the …
[引用][C] Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib …
G Giaccone, D Johnson, GV Scagliotti, C Manegold… - Proc Am Soc Clin Oncol, 2003